Log in

Creso Pharma Limited (CPH.AX) Stock Forecast, Price & News

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Creso Pharma Limited develops, registers, and commercializes pharmaceutical-grade cannabis and hemp-based nutraceutical products and treatments for human and animal health in Europe, the Middle East, and the Asia Pacific. The company is involved in hemp growing operations, outsourced CBD extraction, and cannabidiol (CBD) product sales activities, as well as the development and commercialization of its therapeutic products. Its products include anibidiol, a natural complementary feed product for companion animals; and cannaQIX, a nutraceutical product containing organic hemp extract with CBD vitamins and zinc to reduce stress and support mental and nervous functions in humans, as well as topical and skin care products. The company also offers various nutraceutical products, such as cannaQIX®nite to aid sleep; cannaPEAL to introduce various markets to the benefits of hemp seed oil-based products; and cannaDOL to provide relief to athletes in the form of a topical application. In addition, it imports and sells its medicinal cannabis product, cannaQIX50 to patients in Brazil. Creso Pharma Limited has a strategic collaboration agreement with Hempmate AG Switzerland and Burleigh Heads Cannabis Pty Ltd. The company was incorporated in 2015 and is headquartered in Sydney, Australia.

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.00 out of 5 stars

Industry, Sector and Symbol

Industry Drug Manufacturers—Specialty & Generic
Phone61 2 8067 8606



Sales & Book Value

Annual Sales$4.17 million
Book ValueA$0.02 per share



Next Earnings DateN/A
OptionableNot Optionable

Receive CPH News and Ratings via Email

Sign-up to receive the latest news and ratings for CPH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Creso Pharma Limited (CPH.AX) (ASX:CPH) Frequently Asked Questions

What stocks does MarketBeat like better than Creso Pharma Limited (CPH.AX)?

Wall Street analysts have given Creso Pharma Limited (CPH.AX) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Creso Pharma Limited (CPH.AX) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of Creso Pharma Limited (CPH.AX)'s key competitors?

Who are Creso Pharma Limited (CPH.AX)'s key executives?

Creso Pharma Limited (CPH.AX)'s management team includes the following people:
  • Mr. Adam Blumenthal B.Com., M.B.A., Co-Founder & Non-Exec. Chairman
  • Mr. Boaz Wachtel, Co-Founder & Non-Exec. Director (Age 60, Pay $105k)
  • Dr. Miriam Halperin Wernli, Co-Founder, Head of Technology, Innovation & Distribution and Director
  • Mr. Chris Grundy, Chief Financial Officer
  • Dr. James Anthony Ellingford M.B.A., Ph.D., PG(Corp Mgmt), D.Mgt, MBA, AICD, Exec. Director
  • Dr. Gian Trepp, Commercial & Marketing Director
  • Ms. Erlyn Saromines Dale A.C.I.S., B.Com., BCom., GradDipACG, AGIA, ACIS, Joint Company Sec.
  • Mr. Winton William Willesee BBus, BBus., C.P.A., DipEd, DipEd., PGDipBus, PGDi, Joint Company Sec.
  • Dr. Simon H. W. Buckingham, Consultant (Age 58)

What is Creso Pharma Limited (CPH.AX)'s stock symbol?

Creso Pharma Limited (CPH.AX) trades on the ASX under the ticker symbol "CPH."

How big of a company is Creso Pharma Limited (CPH.AX)?

Creso Pharma Limited (CPH.AX) has a market capitalization of $0.00 and generates $4.17 million in revenue each year.

What is Creso Pharma Limited (CPH.AX)'s official website?

The official website for Creso Pharma Limited (CPH.AX) is www.cresopharma.com.

How can I contact Creso Pharma Limited (CPH.AX)?

The company can be reached via phone at 61 2 8067 8606.

This page was last updated on 12/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.